OSE Immunotherapeutics SA (EPA:OSE)
France
· Delayed Price · Currency is EUR 4.018
-0.042 (-1.03%)
Mar 6, 2026, 5:35 PM CET
OSE Immunotherapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1.78 | 69.88 | 2.23 | 18.3 | 26.31 | Upgrade
|
| Other Revenue | - | 13.56 | - | - | - | Upgrade
|
| Revenue | 1.78 | 83.44 | 2.23 | 18.3 | 26.31 | Upgrade
|
| Revenue Growth (YoY) | -97.86% | 3646.52% | -87.83% | -30.43% | 152.48% | Upgrade
|
| Gross Profit | 1.78 | 83.44 | 2.23 | 18.3 | 26.31 | Upgrade
|
| Selling, General & Admin | 6.86 | 6.26 | 5.96 | 6.59 | 8.5 | Upgrade
|
| Research & Development | 25.6 | 30.45 | 17.09 | 26.82 | 30.49 | Upgrade
|
| Other Operating Expenses | - | 0.27 | 0.13 | 0.24 | 0.16 | Upgrade
|
| Operating Expenses | 32.46 | 39.7 | 25.21 | 36.78 | 42.93 | Upgrade
|
| Operating Income | -30.68 | 43.74 | -22.99 | -18.48 | -16.63 | Upgrade
|
| Interest Expense | - | -3.17 | -2.2 | -1.37 | -0.84 | Upgrade
|
| Interest & Investment Income | 0.38 | 1.47 | 0.34 | 0.02 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.02 | -0.04 | -0 | 0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.23 | -2.41 | 1.66 | 1.82 | 0.2 | Upgrade
|
| EBT Excluding Unusual Items | -32.52 | 39.6 | -23.23 | -18.02 | -17.22 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.23 | 0 | - | 0 | Upgrade
|
| Pretax Income | -32.52 | 39.83 | -23.22 | -18.02 | -17.21 | Upgrade
|
| Income Tax Expense | - | 2.39 | -0.22 | -0.26 | -0.36 | Upgrade
|
| Net Income | -32.52 | 37.45 | -23 | -17.76 | -16.85 | Upgrade
|
| Net Income to Common | -32.52 | 37.45 | -23 | -17.76 | -16.85 | Upgrade
|
| Shares Outstanding (Basic) | 22 | 22 | 20 | 19 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 22 | 26 | 20 | 19 | 18 | Upgrade
|
| Shares Change (YoY) | -14.22% | 31.11% | 5.58% | 2.05% | 16.71% | Upgrade
|
| EPS (Basic) | -1.48 | 1.72 | -1.18 | -0.96 | -0.93 | Upgrade
|
| EPS (Diluted) | -1.48 | 1.46 | -1.18 | -0.96 | -0.93 | Upgrade
|
| Free Cash Flow | -27.05 | 48.36 | -19.78 | -18.53 | -10.39 | Upgrade
|
| Free Cash Flow Per Share | -1.23 | 1.89 | -1.01 | -1.00 | -0.57 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -1721.44% | 52.42% | -1032.15% | -100.96% | -63.20% | Upgrade
|
| Profit Margin | -1824.86% | 44.88% | -1032.91% | -97.04% | -64.05% | Upgrade
|
| Free Cash Flow Margin | -1518.01% | 57.97% | -888.19% | -101.22% | -39.50% | Upgrade
|
| EBITDA | -29.47 | 43.95 | -20.31 | -15.68 | -14.66 | Upgrade
|
| EBITDA Margin | - | 52.67% | - | -85.69% | -55.71% | Upgrade
|
| D&A For EBITDA | 1.21 | 0.21 | 2.68 | 2.8 | 1.97 | Upgrade
|
| EBIT | -30.68 | 43.74 | -22.99 | -18.48 | -16.63 | Upgrade
|
| EBIT Margin | - | 52.42% | - | -100.96% | -63.20% | Upgrade
|
| Effective Tax Rate | - | 5.99% | - | - | - | Upgrade
|
| Revenue as Reported | - | - | - | 18.3 | 26.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.